Cahill Represents Lead Arrangers in $200 Million Credit Facility for BioMarin Pharmaceutical Inc.
Date: 05/28/21
Cahill represented the lead arrangers in connection with an amendment to the $200,000,000 revolving credit facility for BioMarin Pharmaceutical Inc. Proceeds from the credit facility will be used for general corporate purposes. BioMarin is a world leader in developing and commercializing innovative biopharmaceuticals for rare diseases driven by genetic causes.